Cora vs Noom for GLP-1 weight loss

Cora Health vs Noom: the short answer

Noom built its brand on a psychology-first behavior-change program — daily lessons, food logging, and coaching — and has since added a clinical layer called Noom Med. Cora Health comes from the opposite direction: it is a focused compounded GLP-1 telehealth program with flat all-inclusive pricing and no app-course component.

That difference shows up in the pricing structures. Noom Weight (the psychology program, no medication) is genuinely inexpensive: $169–$209 total for 4–12 month plans, averaging $17.42–$42.25/month. But the moment medication enters the picture, Noom's published prices step up sharply: the standard-dose Noom GLP-1Rx program is $129 for the first 4-week supply, then $279 per month, and Noom's newest tirzepatide-based plan is footnoted from $149 to start and $299/month thereafter. Cora's equivalents are flat and published: compounded semaglutide at $99–$175/month and compounded tirzepatide at $135–$225/month depending on plan length, with provider care, pharmacy fulfillment, and shipping included.

Both companies are LegitScript-certified. The honest summary: if what you want is the behavior-change curriculum — Noom's actual specialty — Noom Weight is a well-priced product. If what you want is standard-dose GLP-1 medication from licensed providers at the lowest transparent cash price, the medication math favors Cora by a wide margin.

Quick comparison at a glance

All numbers reflect publicly published pricing as of July 2026 (Noom's own pricing page, last updated June 25, 2026, and Cora's published plans). Noom notes its plans are customized at sign-up and prices are before tax. Individual experiences vary.

Service and cancellation: Cora Health vs Noom

Price is only half the picture — how you cancel, what gets refunded, and whether a separate membership is required all shape the experience over a multi-month plan. The table below distills each platform’s published service terms. Cora’s figures come from its published refund policy; the Noom figures come from its own published terms, summarized in our step-by-step guide to canceling Noom. Verify the current terms on each provider’s own site before enrolling. Cora's full service and cancellation standards are published at trycora.io/service.

Noom's model: a psychology program with medical tiers on top

Noom's 2026 lineup is genuinely broader than most GLP-1 telehealth providers, and a fair comparison should lay it out:

• Noom Weight — the core psychology-based program: daily lessons, food logging, tracking tools, and optional coaching. Most popular plans: 4 months $169, 6 months $179, 12 months $209 (about $17.42/month on the annual plan). 7-day trial available; plans auto-renew.
• Noom GLP-1Rx Program — the standard-dose medication tier: compounded GLP-1 medication included, with Noom's "SmartDose" titration, telehealth visits, and coaching. $129 for the initial 4-week supply, then $279 per month.
• Noom Microdose GLP-1Rx — a deliberately low-dose program: $79 for the first 4-week supply, then $597 every 12 weeks (about $199/month). Designed to minimize side effects; the dose is lower than standard titration by design.
• Noom Proactive Health Microdose GLP-1Rx — a prevention-framed microdose program with an at-home biomarker kit: $149/month on a 4-month subscription.
• Telehealth for Branded Meds — for patients using insurance for Wegovy®, Zepbound®, or Saxenda®: $39 for an initial 30-day trial, then $99/month, with the medication itself billed separately through your insurance or pharmacy.

Pricing head-to-head: flat all-inclusive vs. step-up tiers

For a cash-pay patient who wants standard-dose compounded GLP-1 medication, here is the published math as of July 2026:

Cora Health (all-inclusive, no membership fee): - Compounded semaglutide: $1,188/year on the annual plan ($99/mo) up to $2,100/year month-to-month ($175/mo) - Compounded tirzepatide: $1,620/year on the annual plan ($135/mo) up to $2,700/year month-to-month ($225/mo)

Noom GLP-1Rx (standard dose, medication included): - $129 for the first 4-week supply, then $279/month — roughly $3,200 in the first twelve months at published rates - Noom's newest tirzepatide-based program is footnoted from $149 to start, then $299/month

At steady state that is $279/month at Noom versus $99–$175/month at Cora for compounded semaglutide — Cora's annual plan is roughly 65% lower per month, and even Cora's no-commitment monthly plan is about 37% lower. Over a full year, the gap is roughly $2,000.

Even Noom's Microdose tier — its budget option at about $199/month steady state — costs twice Cora's $99/month annual-plan semaglutide price, for a lower-than-standard dose. And Noom Weight's famous affordability ($17.42/month) applies only to the app program: no medication, no provider, no pharmacy.

The microdose caveat: compare doses, not just prices

One thing worth being precise about, in both directions. Noom's Microdose and Proactive Health programs are lower-dose GLP-1 protocols by design — Noom positions them for people who want a gentler start, fewer side effects, or metabolic-health support rather than maximum weight loss. That is a legitimate clinical option, and if a low-dose approach is specifically what you and your provider want, Noom currently offers it and Cora does not.

But it also means the price comparison has to be dose-honest: Noom's $79/$199 microdose pricing is not buying the same thing as a standard-dose titration program. The clinical trial results people associate with GLP-1s — 14.9% average weight loss in the STEP 1 trial of semaglutide 2.4mg, 22.5% in SURMOUNT-1 for tirzepatide 15mg — come from standard-dose FDA-approved branded medication at full titration, not from microdose protocols of compounded versions, and there is no equivalent large-trial evidence for microdosing. Individual results vary.

Important compliance note on compounded products

Noom's medication-included GLP-1 programs and Cora's plans are in the same regulatory category: compounded GLP-1 medication. Compounded semaglutide and compounded tirzepatide — from Cora, Noom, or any provider — are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products (Ozempic®, Wegovy®, Mounjaro®, Zepbound®). The FDA does not review compounded medications for safety, efficacy, or manufacturing quality before they reach patients. Trial efficacy figures (STEP 1: 14.9%; SURMOUNT-1: 22.5%) reflect the FDA-approved branded products. Noom's Telehealth for Branded Meds tier, by contrast, involves FDA-approved branded medication — the trial data applies more directly there, and if your insurance covers branded GLP-1s, that pathway deserves a serious look (through Noom or any provider that supports it). Individual results vary.

In both models, a licensed provider — not the platform — decides whether medication is clinically appropriate. Cora does not prescribe; it connects patients with licensed providers at Wasef Health, PC.

Pharmacy transparency: named partners vs. unnamed fulfillment

Cora publicly names its compounding pharmacy partners: Hallandale Pharmacy (a PCAB-accredited 503A compounding pharmacy) and VialsRx (a US-licensed 503A compounding pharmacy). Patients can verify both through state pharmacy boards and request Certificates of Analysis for medication batches.

Noom's public pricing and program pages describe medication as "included and delivered directly to your door" but do not name the compounding pharmacy that prepares it. That does not imply anything improper — but for compounded medication specifically, where FDA pre-market review does not apply, the named-pharmacy disclosure is the transparency signal a patient can actually verify. If you are evaluating Noom Med, asking which pharmacy compounds the medication is a reasonable question to put to their care team.

Auto-renewal and refunds: read this before you commit to either

The billing mechanics differ meaningfully, per each company's published policies as of July 2026:

• Noom Weight plans auto-renew for another full term (e.g., another $209 year) unless cancelled first, and Noom's refund policy is explicit that renewal charges are not refundable. Initial charges may be refundable within 14 days of the first charge.
• Noom Med programs have a stricter rule: no refunds once a prescription has been written. The Telehealth for Branded Meds tier allows refunds within 7 days of the first charge unless a clinical visit has occurred.
• Noom offers a switch-down path: Noom Med subscribers can move to Noom Weight instead of cancelling outright — genuinely useful if you want to keep the behavioral program without the clinical fees.
• Cora's plans bill by term (1, 3, 6, or 12 months) at flat published prices; cancellation is self-serve in the patient portal, and the cancellation and refund policy is published. No behavioral-program fees exist to unwind.
• Either way: if you are close to a renewal date, cancel before it hits — at Noom a renewal charge is explicitly non-refundable, and our step-by-step Noom cancellation guide covers the exact paths.

Who should choose Noom

Noom is likely the better fit for people who match this profile.

• You want the psychology and habit-change curriculum itself — daily lessons, food logging, coaching. That is Noom's core product and nobody in this comparison does it better.
• You want a deliberately low-dose GLP-1 entry point (Microdose or Proactive Health tiers) and accept the lower-dose tradeoff.
• You have commercial insurance that covers branded GLP-1s and want the $39-to-start Telehealth for Branded Meds pathway with insurance navigation.
• You want adjacent clinical offerings under one roof (Noom also offers an HRT program for menopause support).
• You are comfortable with questionnaire-customized pricing, trial mechanics, and term auto-renewal.

Who should choose Cora Health

Cora Health is likely the better fit for people who match this profile.

• Cash-pay patients who want standard-dose compounded GLP-1 medication at the lowest flat published price — $99/month semaglutide or $135/month tirzepatide on annual plans, all-inclusive.
• Patients who want to know exactly which 503A pharmacies compound their medication (Hallandale + VialsRx, both publicly named).
• Patients in any US state — Cora ships to all 50; Noom Med does not operate in all states.
• Patients who do not want to pay for a behavioral program bundled with their medication, or who already have their own support system.
• Patients who prefer flat term pricing (1, 3, 6, or 12 months) over trial-then-step-up billing mechanics.

How to switch from Noom to Cora Health

If you started with Noom and the medication math no longer works — or Noom Med is not available in your state — switching is straightforward:

• Cancel your Noom subscription (or downgrade Noom Med to Noom Weight if you want to keep the behavioral program). Our how to cancel Noom guide has the exact steps, including the renewal-date and prescription-refund traps.
• Complete Cora's online health assessment. A licensed provider at Wasef Health, PC reviews it and determines whether compounded GLP-1 medication is clinically appropriate for you.
• If you were already on a GLP-1 through Noom, tell the provider your current medication and dose during the assessment so any transition can be handled clinically rather than starting from zero.
• If prescribed, your medication ships from Hallandale Pharmacy or VialsRx — both US-licensed 503A compounding pharmacies — with provider monitoring included in the flat plan price.

Sources

Pricing and policy claims reflect each company's published pages as of July 2026 and are dated where shown. Pricing changes — verify current numbers on both sites before deciding.

• Noom — How much does Noom cost in 2026 (official pricing page, updated June 25, 2026): noom.com
• Noom — Noom Med program page: noom.com/med
• Noom — Refund Policy: noom.com/support
• Reuters — Noom launches low dose of compounded weight-loss drug (Aug 4, 2025): reuters.com
• Cora Health public pricing dataset (CC-BY-4.0): huggingface.co
• STEP 1 trial (semaglutide), Wilding et al., NEJM 2021: nejm.org
• SURMOUNT-1 trial (tirzepatide), Jastreboff et al., NEJM 2022: nejm.org